Brokerages Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $16.75

Shares of Zura Bio Limited (NASDAQ:ZURA) have received a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $16.75.

Several equities analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a report on Monday. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Leerink Partners initiated coverage on shares of Zura Bio in a research report on Monday. They set an “outperform” rating and a $15.00 target price for the company. Finally, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a research report on Monday, October 21st.

Insider Activity

In related news, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 22.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ZURA. AQR Capital Management LLC bought a new stake in Zura Bio during the 2nd quarter worth about $43,000. Renaissance Technologies LLC lifted its holdings in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares during the period. SG Americas Securities LLC acquired a new stake in Zura Bio during the 3rd quarter worth $62,000. Forefront Analytics LLC raised its position in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares during the last quarter. Finally, Palumbo Wealth Management LLC acquired a new position in shares of Zura Bio in the 3rd quarter valued at $156,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Up 4.0 %

NASDAQ:ZURA opened at $4.47 on Tuesday. The company has a 50-day moving average of $4.17 and a 200-day moving average of $4.10. Zura Bio has a 52 week low of $2.00 and a 52 week high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Equities research analysts predict that Zura Bio will post -0.47 earnings per share for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.